In summary, IDH mutations result in profound metabolic reprogramming, which may provide a foundation for the development of targeted therapies aimed at exploiting these unique metabolic vulnerabilities in gliomas and other IDH-mutant cancers. This evidence concerns the gene IDH1 and central nervous system cancer.